Eloquest Healthcare and Omni-stat Forge Alliance to Enhance Hemostatic Solutions within Acute Care Settings

Eloquest Healthcare Partners with Omni-stat Medical for Enhanced Acute Care Solutions

In a significant development for the healthcare industry, Eloquest Healthcare, Inc., a recognized leader in infection prevention and vascular access solutions, has announced a strategic partnership with Omni-stat Medical, Inc., a global innovator specializing in hemostatic technologies. The collaboration, revealed on October 7, 2025, aims to boost the accessibility and implementation of advanced hemostatic products within the U.S. acute care market, specifically targeting intensive care units (ICUs) and vascular access procedures.

The portfolio introduced by Omni-stat includes proprietary hemostatic gauze, engineered to swiftly and effectively manage bleeding—a critical concern in emergency medical situations. Clinicians working in high-stakes environments like ICUs are often pressed for time, making these reliable solutions essential. As such, this partnership aligns perfectly with Eloquest Healthcare’s overarching mission: to enhance patient outcomes and elevate care standards related to vascular access management.

Tim O'Halla, the President and CEO of Eloquest Healthcare, expressed enthusiasm over this collaboration, stating, "We are excited to partner with Omni-stat Medical to bring these proven hemostatic solutions into more hospitals and ICUs across the country. This agreement reflects our continued commitment to aligning with best-in-class technologies that complement our portfolio. Together, we can help clinicians improve care and outcomes for patients at some of the most challenging points in their treatment journey."

On the flip side, Gina Milner, the Director of US Commercial Operations at Omni-stat Medical, highlighted the significance of this partnership by saying, "Omni-Stat is proud to collaborate with Eloquest Healthcare. Their deep expertise and trusted presence in the acute care market make them the ideal partner to expand adoption of our hemostatic products. We look forward to working together to support clinicians with more effective solutions that rapidly reduce blood loss and save time, ultimately improving safety and enhancing patient care."

About Eloquest Healthcare, Inc.

Eloquest Healthcare, Inc. operates as a wholly owned subsidiary of Ferndale Pharma Group, Inc. The company is dedicated to offering streamlined solutions that not only improve clinical outcomes but also enhance the quality of care provided to patients. They focus on reducing overall care costs and improving staff efficiency, thus striving for operational excellence across the healthcare spectrum.

For further information, visit Eloquest Healthcare.

About Omni-stat Medical, Inc.

On the other hand, Omni-stat Medical is a forerunner in the field of hemostatic technologies. Their products are developed with the goal of providing rapid and effective control of minor to severe bleeding incidents. Committed to innovation, Omni-stat aims to facilitate shorter patient stays while optimizing staffing resources by minimizing blood loss and associated complications.

To learn more, visit Omni-stat Medical.

This partnership between Eloquest and Omni-stat exemplifies the synergy between innovative technology and patient care within the medical community, showcasing the potential for improved outcomes in critical care settings.